The evolving field of human papillomavirus receptor research: A review of binding and entry

Journal of Virology

Volumn 87, Issue 11, 2013, Pages 6062-6072

  Raff, Adam B ^a,d   Woodham, Andrew W ^b   Raff, Laura M ^b   Skeate, Joseph G ^b   Yan, Lisa ^b   Da Silva, Diane M ^a,b   Schelhaas, Mario ^c   Kast, W Martin ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA6 INTEGRIN; CAPSID PROTEIN L1; CYCLOPHILIN B; EPIDERMAL GROWTH FACTOR RECEPTOR; FURIN; KALININ; KERATINOCYTE GROWTH FACTOR RECEPTOR; LIPOCORTIN 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEOHEPARAN SULFATE; TETRASPANIN;

BASEMENT MEMBRANE; CELL SURFACE; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; ENDOCYTOSIS; EPITHELIUM CELL; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; INTRACELLULAR SIGNALING; ISOMERIZATION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; VIRION; VIRUS ATTACHMENT; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS LIKE AGENT; VIRUS MORPHOLOGY;

ALPHAPAPILLOMAVIRUS; ANIMALS; HEPARAN SULFATE PROTEOGLYCANS; HUMAN PAPILLOMAVIRUS 16; HUMANS; PAPILLOMAVIRUS INFECTIONS; RECEPTORS, VIRUS; VIRUS INTERNALIZATION;

EID: 84878199077     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00330-13     Document Type: Short Survey

References (105)

1. Marsh M, Helenius A. 2006. Virus entry: open sesame. Cell 124:729- 740.
2. Mercer J, Schelhaas M, Helenius A. 2010. Virus entry by endocytosis. Annu. Rev. Biochem. 79:803- 833.
3. Sieczkarski SB, Whittaker GR. 2005. Viral entry. Curr. Top. Microbiol. Immunol. 285:1-23.
4. Modis Y, Trus BL, Harrison SC. 2002. Atomic model of the papillomavirus capsid. EMBO J. 21:4754-4762.
5. Buck CB, Cheng N, Thompson CD, Lowy DR, Steven AC, Schiller JT, Trus BL. 2008. Arrangement of L2 within the papillomavirus capsid. J. Virol. 82:5190 -5197.
6. Baker TS, Newcomb WW, Olson NH, Cowsert LM, Olson C, Brown JC. 1991. Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys. J. 60:1445-1456.
7. Kondo K, Ishii Y, Ochi H, Matsumoto T, Yoshikawa H, Kanda T. 2007. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 358:266 -272.
8. Finnen RL, Erickson KD, Chen XS, Garcea RL. 2003. Interactions between papillomavirus L1 and L2 capsid proteins. J. Virol. 77:4818- 4826.
9. Unckell F, Streeck RE, Sapp M. 1997. Generation and neutralization of pseudovirions of human papillomavirus type 33. J. Virol. 71:2934 -2939.
10. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. 1998. In vitro construction of pseudovirions of human papillomavirus type 16: incorporation of plasmid DNA into reassembled L1/L2 capsids. J. Virol. 72:10298 -10300.
11. Zhou J, Sun XY, Louis K, Frazer IH. 1994. Interaction of human papillomavirus (HPV) type 16 capsid proteins with HPV DNA requires an intact L2 N-terminal sequence. J. Virol. 68:619-625.
12. Zhao KN, Sun XY, Frazer IH, Zhou J. 1998. DNA packaging by L1 and L2 capsid proteins of bovine papillomavirus type 1. Virology 243:482- 491.
13. Buck CB, Thompson CD, Pang YY, Lowy DR, Schiller JT. 2005. Maturation of papillomavirus capsids. J. Virol. 79:2839 -2846.
14. Holmgren SC, Patterson NA, Ozbun MA, Lambert PF. 2005. The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle. J. Virol. 79:3938 -3948.
15. Kämper N, Day PM, Nowak T, Selinka HC, Florin L, Bolscher J, Hilbig L, Schiller JT, Sapp M. 2006. A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J. Virol. 80:759 -768.
16. Bronnimann MP, Chapman JA, Park CK, Campos SK. 2013. A transmembrane domain and GxxxG motifs within L2 are essential for papillomavirus infection. J. Virol. 87:464-473.
17. Bergant Marušič M, Ozbun MA, Campos SK, Myers MP, Banks L. 2012. Human papillomavirus L2 facilitates viral escape from late endosomes via sorting nexin 17. Traffic 13:455- 467.
18. Yang R, Yutzy WH, IV, Viscidi RP, Roden RB. 2003. Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection. J. Biol. Chem. 278:12546 -12553.
19. Schneider MA, Spoden GA, Florin L, Lambert C. 2011. Identification of the dynein light chains required for human papillomavirus infection. Cell. Microbiol. 13:32- 46.
20. Day PM, Baker CC, Lowy DR, Schiller JT. 2004. Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proc. Natl. Acad. Sci. U. S. A. 101:14252-14257.
21. Ishii Y, Ozaki S, Tanaka K, Kanda T. 2005. Human papillomavirus 16 minor capsid protein L2 helps capsomeres assemble independently of intercapsomeric disulfide bonding. Virus Genes 31:321-328.
22. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. 1992. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. U. S. A. 89:12180- 12184.
23. Zhou J, Sun XY, Stenzel DJ, Frazer IH. 1991. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185:251-257.
24. Hagensee ME, Yaegashi N, Galloway DA. 1993. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J. Virol. 67:315-322.
25. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, Lowy DR, Schiller JT. 1993. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 67:6929- 6936.
26. Hofmann KJ, Cook JC, Joyce JG, Brown DR, Schultz LD, George HA, Rosolowsky M, Fife KH, Jansen KU. 1995. Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology 209:506 -518.
27. Roden RB, Greenstone HL, Kirnbauer R, Booy FP, Jessie J, Lowy DR, Schiller JT. 1996. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J. Virol. 70:5875- 5883.
28. Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M. 2001. Human papillomavirus infection requires cell surface heparan sulfate. J. Virol. 75:1565-1570.
29. Buck CB, Pastrana DV, Lowy DR, Schiller JT. 2004. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 78:751-757.
30. Pyeon D, Lambert PF, Ahlquist P. 2005. Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation. Proc. Natl. Acad. Sci. U. S. A. 102:9311-9316.
31. Fligge C, Schafer F, Selinka HC, Sapp C, Sapp M. 2001. DNA-induced structural changes in the papillomavirus capsid. J. Virol. 75:7727-7731.
32. Meyers C, Frattini MG, Hudson JB, Laimins LA. 1992. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 257:971-973.
33. Meyers C, Mayer TJ, Ozbun MA. 1997. Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA. J. Virol. 71:7381-7386.
34. Frattini MG, Lim HB, Doorbar J, Laimins LA. 1997. Induction of human papillomavirus type 18 late gene expression and genomic amplification in organotypic cultures from transfected DNA templates. J. Virol. 71:7068 -7072.
35. Ozbun MA. 2002. Infectious human papillomavirus type 31b: purification and infection of an immortalized human keratinocyte cell line. J. Gen. Virol. 83:2753-2763.
36. Conway MJ, Alam S, Ryndock EJ, Cruz L, Christensen ND, Roden RB, Meyers C. 2009. Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions. J. Virol. 83:10515-10526.
37. Selinka HC, Giroglou T, Nowak T, Christensen ND, Sapp M. 2003. Further evidence that papillomavirus capsids exist in two distinct conformations. J. Virol. 77:12961-12967.
38. Kines RC, Thompson CD, Lowy DR, Schiller JT, Day PM. 2009. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc. Natl. Acad. Sci. U. S. A. 106:20458 -20463.
39. Woodham AW, Da Silva DM, Skeate JG, Raff AB, Ambroso MR, Brand HE, Isas JM, Langen R, Kast WM. 2012. The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS One 7:e43519. doi:10.1371/journal.pone .0043519.
40. Chen HS, Conway MJ, Christensen ND, Alam S, Meyers C. 2011. Papillomavirus capsid proteins mutually impact structure. Virology 412: 378-383.
41. Roden RB, Kirnbauer R, Jenson AB, Lowy DR, Schiller JT. 1994. Interaction of papillomaviruses with the cell surface. J. Virol. 68:7260- 7266.
42. Day PM, Lowy DR, Schiller JT. 2003. Papillomaviruses infect cells via a clathrin-dependent pathway. Virology 307:1-11.
43. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. 1988. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J. Cell Biol. 106:761-771.
44. Abban CY, Meneses PI. 2010. Usage of heparan sulfate, integrins, and FAK in HPV16 infection. Virology 403:1-16.
45. Johnson KM, Kines RC, Roberts JN, Lowy DR, Schiller JT, Day PM. 2009. Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J. Virol. 83:2067- 2074.
46. Joyce JG, Tung JS, Przysiecki CT, Cook JC, Lehman ED, Sands JA, Jansen KU, Keller PM. 1999. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J. Biol. Chem. 274:5810 -5822.
47. Culp TD, Budgeon LR, Marinkovich MP, Meneguzzi G, Christensen ND. 2006. Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells. J. Virol. 80:8940-8950.
48. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. 1999. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68:729 -777.
49. Choi Y, Chung H, Jung H, Couchman JR, Oh ES. 2011. Syndecans as cell surface receptors: unique structure equates with functional diversity. Matrix Biol. 30:93-99.
50. Liu J, Thorp SC. 2002. Cell surface heparan sulfate and its roles in assisting viral infections. Med. Res. Rev. 22:1-25.
51. Carey DJ. 1997. Syndecans: multifunctional cell-surface co-receptors. Biochem. J. 327(Pt 1):1-16.
52. Elenius K, Vainio S, Laato M, Salmivirta M, Thesleff I, Jalkanen M. 1991. Induced expression of syndecan in healing wounds. J. Cell Biol. 114:585-595.
53. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, Lowy DR, Schiller JT. 2007. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat. Med. 13:857- 861.
54. Shafti-Keramat S, Handisurya A, Kriehuber E, Meneguzzi G, Slupetzky K, Kirnbauer R. 2003. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J. Virol. 77: 13125-13135.
55. Huang HS, Lambert PF. 2012. Use of an in vivo animal model for assessing the role of integrin alpha(6)beta(4) and syndecan-1 in early steps in papillomavirus infection. Virology 433:395- 400.
56. Knappe M, Bodevin S, Selinka HC, Spillmann D, Streeck RE, Chen XS, Lindahl U, Sapp M. 2007. Surface-exposed amino acid residues of HPV16 L1 protein mediating interaction with cell surface heparan sulfate. J. Biol. Chem. 282:27913-27922.
57. Dasgupta J, Bienkowska-Haba M, Ortega ME, Patel HD, Bodevin S, Spillmann D, Bishop B, Sapp M, Chen XS. 2011. Structural basis of oligosaccharide receptor recognition by human papillomavirus. J. Biol. Chem. 286:2617-2624.
58. Ozbun MA. 2002. Human papillomavirus type 31b infection of human keratinocytes and the onset of early transcription. J. Virol. 76:11291- 11300.
59. Day PMLD, Schiller JT. 2008. Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids. J. Virol. 82:12565-12568.
60. Schiller JT, Day PM, Kines RC. 2010. Current understanding of the mechanism of HPV infection. Gynecol. Oncol. 118:S12-S17.
61. Schowalter RM, Pastrana DV, Buck CB. 2011. Glycosaminoglycans and sialylated glycans sequentially facilitate Merkel cell polyomavirus infectious entry. PLoS Pathog. 7:e1002161. doi:10.1371/journal.ppat .1002161.
62. Richards RM, Lowy DR, Schiller JT, Day PM. 2006. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc. Natl. Acad. Sci. U. S. A. 103:1522-1527.
63. Day PM, Gambhira R, Roden RB, Lowy DR, Schiller JT. 2008. Mechanisms of human papillomavirus type 16 neutralization by l2 crossneutralizing and l1 type-specific antibodies. J. Virol. 82:4638-4646.
64. Bienkowska-Haba M, Patel HD, Sapp M. 2009. Target cell cyclophilins facilitate human papillomavirus type 16 infection. PLoS Pathog. 5:e1000524. doi:10.1371/journal.ppat.1000524.
65. Fischer G, Wittmann-Liebold B, Lang K, Kiefhaber T, Schmid FX. 1989. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 337:476-478.
66. Pakula R, Melchior A, Denys A, Vanpouille C, Mazurier J, Allain F. 2007. Syndecan-1/CD147 association is essential for cyclophilin B-induced activation of p44/42 mitogen-activated protein kinases and promotion of cell adhesion and chemotaxis. Glycobiology 17:492-503.
67. Bienkowska-Haba M, Williams C, Kim SM, Garcea RL, Sapp M. 2012. Cyclophilins facilitate dissociation of the HPV16 capsid protein L1 from the L2/DNA complex following virus entry. J. Virol. 86:9875-9887.
68. Seidah NG, Prat A. 2012. The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov. 11:367-383.
69. Selinka HC, Florin L, Patel HD, Freitag K, Schmidtke M, Makarov VA, Sapp M. 2007. Inhibition of transfer to secondary receptors by heparan sulfate-binding drug or antibody induces noninfectious uptake of human papillomavirus. J. Virol. 81:10970 -10980.
70. Yoon CS, Kim KD, Park SN, Cheong SW. 2001. alpha(6) integrin is the main receptor of human papillomavirus type 16 VLP. Biochem. Biophys. Res. Commun. 283:668-673.
71. Evander M, Frazer IH, Payne E, Qi YM, Hengst K, McMillan NA. 1997. Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J. Virol. 71:2449 -2456.
72. Roper JA, Williamson RC, Bass MD. 2012. Syndecan and integrin interactomes: large complexes in small spaces. Curr. Opin. Struct. Biol. 22:583-590.
73. Melchior A, Denys A, Deligny A, Mazurier J, Allain F. 2008. Cyclophilin B induces integrin-mediated cell adhesion by a mechanism involving CD98-dependent activation of protein kinase C-delta and p44/42 mitogen-activated protein kinases. Exp. Cell Res. 314:616-628.
74. Fothergill T, McMillan NA. 2006. Papillomavirus virus-like particles activate the PI3-kinase pathway via alpha-6 beta-4 integrin upon binding. Virology 352:319 -328.
75. Schelhaas M, Shah B, Holzer M, Blattmann P, Kuhling L, Day PM, Schiller JT, Helenius A. 2012. Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis. PLoS Pathog. 8:e1002657. doi:10.1371/journal.ppat.1002657.
76. Surviladze Z, Sterk RT, Deharo SA, Ozbun MA. 2013. Cellular entry of human papillomavirus type 16 involves activation of the PI3K/Akt/ mTOR pathway and inhibition of autophagy. J. Virol. 87:2508 -2517.
77. Surviladze Z, Dziduszko A, Ozbun MA. 2012. Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections. PLoS Pathog. 8:e1002519. doi:10 .1371/journal.ppat.1002519.
78. de Giorgi V, Sestini S, Massi D, Ghersetich I, Lotti T. 2007. Keratinocyte growth factor receptors. Dermatol. Clin. 25:477- 485, vii. 79. Reference deleted.
79. Reference deleted
80. Li J, Lin ML, Wiepz GJ, Guadarrama AG, Bertics PJ. 1999. Integrinmediated migration of murine B82L fibroblasts is dependent on the expression of an intact epidermal growth factor receptor. J. Biol. Chem. 274:11209 -11219.
81. Miyamoto S, Teramoto H, Gutkind JS, Yamada KM. 1996. Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors. J. Cell Biol. 135:1633-1642.
82. Spoden G, Freitag K, Husmann M, Boller K, Sapp M, Lambert C, Florin L. 2008. Clathrin- and caveolin-independent entry of human papillomavirus type 16 -involvement of tetraspanin-enriched microdomains (TEMs). PLoS One 3:e3313. doi:10.1371/journal.pone .0003313.
83. Hemler ME. 2003. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu. Rev. Cell Dev. Biol. 19:397- 422.
84. Levy S, Shoham T. 2005. Protein-protein interactions in the tetraspanin web. Physiology (Bethesda) 20:218 -224.
85. Scheffer KD, Gawlitza A, Spoden GA, Zhang XA, Lambert C, Berditchevski F, Florin L. 2013. Tetraspanin CD151 mediates papillomavirus type 16 endocytosis. J. Virol. 87:3435-3446
86. Sterk LM, Geuijen CA, van den Berg JG, Claessen N, Weening JJ, Sonnenberg A. 2002. Association of the tetraspanin CD151 with the laminin-binding integrins alpha3beta1, alpha6beta1, alpha6beta4 and alpha7beta1 in cells in culture and in vivo. J. Cell Sci. 115:1161-1173.
87. Volpers C, Schirmacher P, Streeck RE, Sapp M. 1994. Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells. Virology 200:504 -512.
88. Kawana Y, Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. 2001. Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm. J. Virol. 75:2331-2336.
89. Willis SH, Rux AH, Peng C, Whitbeck JC, Nicola AV, Lou H, Hou W, Salvador L, Eisenberg RJ, Cohen GH. 1998. Examination of the kinetics of herpes simplex virus glycoprotein D binding to the herpesvirus entry mediator, using surface plasmon resonance. J. Virol. 72:5937-5947.
90. Casasnovas JM, Springer TA. 1995. Kinetics and thermodynamics of virus binding to receptor. Studies with rhinovirus, intercellular adhesion molecule-1 (ICAM-1), and surface plasmon resonance. J. Biol. Chem. 270:13216 -13224.
91. Waisman DM. 1995. Annexin II tetramer: structure and function. Mol. Cell. Biochem. 149-150:301-322.
92. Rescher U, Gerke V. 2008. S100A10/p11: family, friends and functions. Pflugers Arch. 455:575-582.
93. Gerke V, Creutz CE, Moss SE. 2005. Annexins: linking Ca2+ signalling to membrane dynamics. Nat. Rev. Mol. Cell Biol. 6:449-461.
94. Ma G, Greenwell-Wild T, Lei K, Jin W, Swisher J, Hardegen N, Wild CT, Wahl SM. 2004. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J. Exp. Med. 200:1337-1346.
95. Wright JF, Kurosky A, Wasi S. 1994. An endothelial cell-surface form of annexin II binds human cytomegalovirus. Biochem. Biophys. Res. Commun. 198:983-989.
96. Raynor CM, Wright JF, Waisman DM, Pryzdial EL. 1999. Annexin II enhances cytomegalovirus binding and fusion to phospholipid membranes. Biochemistry 38:5089 -5095.
97. Malhotra R, Ward M, Bright H, Priest R, Foster MR, Hurle M, Blair E, Bird M. 2003. Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells. Microbes Infect. 5:123-133.
98. Yang SL, Chou YT, Wu CN, Ho MS. 2011. Annexin II binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity. J. Virol. 85:11809 -11820.
99. Compton T. 2004. Receptors and immune sensors: the complex entry path of human cytomegalovirus. Trends Cell Biol. 14:5- 8.
100. Schelhaas M, Ewers H, Rajamaki ML, Day PM, Schiller JT, Helenius A. 2008. Human papillomavirus type 16 entry: retrograde cell surface transport along actin-rich protrusions. PLoS Pathog. 4:e1000148. doi:10.1371 /journal.ppat.1000148.
101. Smith JL, Lidke DS, Ozbun MA. 2008. Virus activated filopodia promote human papillomavirus type 31 uptake from the extracellular matrix. Virology 381:16 -21.
102. Lidke DS, Lidke KA, Rieger B, Jovin TM, Arndt-Jovin DJ. 2005. Reaching out for signals: filopodia sense EGF and respond by directed retrograde transport of activated receptors. J. Cell Biol. 170:619-626.
103. Williams KJ, Fuki IV. 1997. Cell-surface heparan sulfate proteoglycans: dynamic molecules mediating ligand catabolism. Curr. Opin. Lipidol. 8:253-262.
104. Horvath CA, Boulet GA, Renoux VM, Delvenne PO, Bogers JP. 2010. Mechanisms of cell entry by human papillomaviruses: an overview. Virol. J. 7:11.
105. Araki N, Johnson MT, Swanson JA. 1996. A role for phosphoinositide 3-kinase in the completion of macropinocytosis and phagocytosis by macrophages. J. Cell Biol. 135:1249 -1260.